Loading...
Ras prenylation inhibition→apoptosis→colorectal cancer prevention
Statins reduce colorectal cancer risk through mevalonate pathway inhibition, disruption of Ras oncogene prenylation, induction of apoptosis, and anti-inflammatory mechanisms. Evidence quality is strong with 50% support ratio across 229 co-mentions and multiple epidemiological and mechanistic studies. However, biological mechanisms remain incompletely understood and results are somewhat inconsistent.
“This review systematically explores the role of statins in breast and colorectal cancer regulation, covering clinical evidence, underlying biological mechanisms, pharmacological distinctions, synergistic therapeutic potential, and translational medicine prospects.”
— The role of statins in the regulation of breast and colorectal cancer and future directions. (2025)DOI“Statins are first-line drugs used to control patient lipid levels, but there is recent evidence that statin treatment can lower colorectal cancer (CRC) incidence by 50% and prolong CRC patient survival through mechanisms that are poorly understood.”
— Lovastatin Inhibits RhoA to Suppress Canonical Wnt/β-Catenin Signaling and Alternative Wnt-YAP/TAZ Signaling in Colon Cancer. (2022)DOI“Epidemiological evidence suggests that statins prevent colorectal cancer (CRC), but the biological mechanism remains obscure.”
— The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. (2007)DOI“We outlined the protocol of a target trial to estimate the effect of statins on colorectal cancer incidence among adults with low-density lipoprotein (LDL) cholesterol below 5 mmol/L. We then emulated the target trial using linked electronic health records of 752 469 eligible UK adults (CALIBER 1999”
— Emulating a target trial in case-control designs: an application to statins and colorectal cancer. (2020)DOI“Objective: To explore the association between statins and colorectal cancer and provide evidence for the prevention of colorectal cancer.”
— [A Meta-analysis on association between statins and colorectal cancer]. (2021)DOI“Increased mortality from colorectal cancer in younger individuals: The preventive role of aspirin and statins.”
— Increased mortality from colorectal cancer in younger individuals: The preventive role of aspirin and statins. (2025)DOI“Long-term use of statins is associated with a small reduced risk of colorectal cancer but their mechanism of action is not well understood. While they are generally believed to act on KRAS, we have previously proposed that they act via influencing the BMP pathway.”
— Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4. (2021)DOI“Statins exhibit anti-tumor potential by modulating Wnt/β-catenin signaling in colorectal cancer.”
— Statins exhibit anti-tumor potential by modulating Wnt/β-catenin signaling in colorectal cancer. (2025)DOI“Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy.”
— Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy. (2023)DOI“(1) Background: The pleiotropic effects of statins may explain a chemoprotective action against colorectal cancer (CRC).”
— Statins and Colorectal Cancer Risk: A Population-Based Case-Control Study and Synthesis of the Epidemiological Evidence. (2022)DOI“Statins, commonly used to lower cholesterol, are associated with improved prognosis in colorectal cancer (CRC), though their effectiveness varies.”
— Screening of patient-derived organoids identifies mitophagy as a cell-intrinsic vulnerability in colorectal cancer during statin treatment. (2025)DOI“The aim of the present study was to clarify whether statins prevented OIPN in patients with colorectal cancer (CRC) receiving adjuvant CAPOX therapy.”
— Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study. (2023)DOI“Observational studies show statins decrease the risk of developing colorectal cancer but there are no published studies exploring the potential impact of statins on carcinogenesis in colorectal liver metastases (CRLM).”
— Retrospective cohort study of statin therapy effect on resected colorectal liver metastases. (2020)DOI“Statins are reported to reduce colorectal cancer (CRC) risk in the general population, but their effect on individuals with inflammatory bowel disease (IBD) remains uncertain.”
— Statins and the Risk of Colorectal Cancer in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. (2025)DOI“The Relationship between Statins and Survival of Colorectal Cancer.”
— The Relationship between Statins and Survival of Colorectal Cancer. (2023)DOI“Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer.”
— Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer. (2023)DOI